ArticleJournal of fungi (Basel, Switzerland)2022
Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant
Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases.Mycopathologia · 2026Article
- Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.Emerging infectious diseases · 2026Article
- Persistence and spread of fluconazole-resistantMicrobial genomics · 2026Article
- Nine-Year Surveillance ofJournal of fungi (Basel, Switzerland) · 2025Article
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Characterization of COVID-19-Associated Candidemia Among Burn Patients.Journal of clinical laboratory analysis · 2025Article
- Antimicrobial and antiparasitic potential of lupeol: antifungal effect on theJournal of medical microbiology · 2025Article
- Epidemiology of Coronavirus Disease 2019-Associated Fungal Infections in the Intensive Care Unit: A Single-Center Retrospective Study.Mycopathologia · 2025Article
- Changes in Candidemia during the COVID-19 Pandemic: Species Distribution, Antifungal Susceptibility, Initial Antifungal Usage, and Mortality Trends in Two Korean Tertiary Care Hospitals.Chonnam medical journal · 2025Article
- Clinical Characteristics of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2024Article
- Increase in candidemia cases and emergence of fluconazole-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Bloodstream infections in the era of the COVID-19 pandemic: Changing epidemiology of antimicrobial resistance in the intensive care unit.Journal of intensive medicine · 2024Review
- Molecular and Epidemiological Investigation of Fluconazole-resistantOpen forum infectious diseases · 2024Article
- First Canadian report of transmission of fluconazole-resistantJournal of clinical microbiology · 2024Article
- SevereJournal of intensive medicine · 2023Review
- Paradigm Shift:Journal of fungi (Basel, Switzerland) · 2023Article
- Invasive Fungal Infections Associated with COVID-19.Journal of fungi (Basel, Switzerland) · 2023Review
- The Clinical Characteristics of Bloodstream Infections Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Multicentre Surveillance ofMicroorganisms · 2023Article
- The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review.JAC-antimicrobial resistance · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severely ill COVID-19 patients are at high risk of nosocomial infections. The aim of the study was to describe the characteristics of candidemia during the pre-pandemic period (January 2019−February 2020) compared to the pandemic period (March 2020−September 2021). Antifungal susceptibilities were assessed using the EUCAST E.Def 7.3.2 broth dilution method. Fluconazole-resistant C. parapsilosis isolates (FRCP) were studied for sequencing of the ERG11 gene. The incidence of candidemia and C. parapsilosis bloodstream infection increased significantly in the pandemic period (p = 0.021). ICU admission, mechanical ventilation, parenteral nutrition and corticosteroids administration were more frequent in patients with candidemia who had been admitted due to COVID-19. Fifteen cases of FRCP fungemia were detected. The first case was recorded 10 months before the pandemic in a patient transferred from another hospital. The incidence of FRCP in patients admitted for COVID-19 was 1.34 and 0.16 in all other patients (p < 0.001). ICU admission, previous Candida spp. colonization, arterial catheter use, parenteral nutrition and renal function replacement therapy were more frequent in patients with candidemia due to FRCP. All FRCP isolates showed the Y132F mutation. In conclusion, the incidence of candidemia experienced an increase during the COVID-19 pandemic and FRCP fungemia was more frequent in patients admitted due to COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.